Researchers at La Trobe University have built a sensor that mimics the protective surface of gut cells and, in lab tests, ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

Navigating the Future of Cancer Diagnostics and Liquid BiopsyThe global healthcare landscape is witnessing a massive shift toward precision medicine. At the heart of this revolution lies the study of ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a ...

Good morning, everyone, and welcome to the Abeona Therapeutics Full Year 2025 Results Conference Call. [Operator Instructions] Please note this conference is being recor ...

Stephen Willey, Stifel: Asked if the QTC target number has increased. Vasanthavada confirmed the target of 7 centers in 2026 and discussed the benefits of expanding the network. He also detailed ...

Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric ...

First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as of ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression ...